Novo Nordisk A/S (NYSE:NVO) to Issue $1.28 Dividend

Novo Nordisk A/S (NYSE:NVO) announced a dividend on Wednesday, February 4th. Stockholders of record on Monday, March 30th will be given a dividend of 1.2751 per share on Wednesday, April 8th. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th.

Novo Nordisk A/S has raised its dividend payment by an average of 0.2%annually over the last three years. Novo Nordisk A/S has a payout ratio of 17.4% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Novo Nordisk A/S to earn $4.66 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 17.6%.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $3.06 on Thursday, hitting $44.13. The company’s stock had a trading volume of 31,101,247 shares, compared to its average volume of 25,472,236. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The company has a market capitalization of $197.06 billion, a PE ratio of 12.84 and a beta of 0.67. The stock’s 50 day moving average is $53.75 and its 200-day moving average is $54.13. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 4th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NVO. Revolve Wealth Partners LLC increased its position in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the period. AQR Capital Management LLC increased its holdings in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after purchasing an additional 10,758 shares during the period. Sivia Capital Partners LLC raised its position in Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares during the last quarter. OLD National Bancorp IN lifted its holdings in Novo Nordisk A/S by 83.4% during the 2nd quarter. OLD National Bancorp IN now owns 6,903 shares of the company’s stock worth $476,000 after buying an additional 3,140 shares during the period. Finally, Simplicity Wealth LLC grew its position in shares of Novo Nordisk A/S by 7.5% in the 2nd quarter. Simplicity Wealth LLC now owns 3,423 shares of the company’s stock valued at $236,000 after buying an additional 240 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.